One BioSciences, spin-off of the Curie Institute co-founded with Home Biosciences in 2020, raised 15 million euros from worldwide global investors. Born from the pioneering works of Dr Céline Vallot, research team chef at the Institut Curie, the start-up uses the power of the sequencing in single cells combined with artificial intelligence to adapt the treatment of each patient. These funds will allow one biosciences to accelerate the development of its platform to make precision medicine a clinical reality.
Co -founded in 2020 by the Institut Curie et Home Biosciences, One Biosciences is a techbio company specializing in precision oncology. Coming from the innovative work of Dr Céline Vallot, research director at the CNRS and head of the team “Dynamic of epigenetic plasticity in cancer” at the Curie Institute, the start-up is based on unique cell profiling to improve the diagnosis of cancer and guide the therapeutic decision. Accompanied in 2019 as part of the Institut Curie Institute’s incubation program, One BioSciences benefited from tailor -made support, from the first creation phases to its operational development.
“We are proud of the path traveled by One BioSciences, a start-up from the Institut Curie Institute’s incubation program, at the crossroads of two areas of excellence in our institute: the single cell analysis and artificial intelligence. This major fundraising illustrates the quality of the innovations carried by the Curie Institute and confirms the relevance of our support model. It also constitutes a decisive step for One BioSciences, by giving it the means to accelerate the development and placing on the market of rupture technologies, for the benefit of patients. »»
Dr Cécile Campagne Director of valuation and industrial partnerships at the Institut Curie and Deputy Director of Carnot Curie Cancer
Combine technologies in single cell and AI to decipher tumor heterogeneity
One Biosciences attacks one of the most significant challenges of oncology: tumor heterogeneity. By combining advanced expertise in molecular biology and AI, the company creates complete functional profiles of individual patient tumors, decoding complex biology behind resistance to treatments in advanced cancers.
Single cell technologies and analyzes piloted by the AI of One BioSciences provide an OMI profile1 High resolution to support the precise selection of patients, the tangible development of therapies, optimized treatment strategies and the matching of clinical trials.
“One BioSciences was based on the conviction that we can guide the choice of treatment of each patient by introducing analysis into a single cell in clinical routine practice. We can now materialize this vision: the first high resolution profiles will be sent to doctors in less than 2 weeks from 2025. We hope in the long term to change the lives of many patients. Enthuses Dr. Céline Vallot.
Significant fundraising to transform the diagnosis and cancer treatments
One Biosciences announces the completion of its lifting of serial funds A of nearly 15 million euros from global investors2 . This investment will accelerate the development and clinical validation of the ONEMAP ™ flagship platform of One BioSciences, a revolutionary clinical diagnostic platform which combines analysis in single cell and AI. It provides clinicians information on the tumor from samples of routine tumor biopsy, allowing therapeutic decisions based on analysis data in just 2 weeks. OneMap ™ will be validated by studies in real conditions, and compared to existing solutions in several indications in Europe and the United States.
Funding will also support the establishment of strategic partnerships with pharmaceutical and biotechs groups seeking to integrate ONECURE ™, the ONE BioSciences owner’s owner’s offer, in their drug development programs and clinical trials.
Hedi Ben Brahim, CEO of one biosciences, Declared: “This funding allows us to transform our revolutionary technology into real -time results, which will impact the development of drugs and, ultimately, the care received by patients. The extraordinary support that we have received from a group of global leaders investors strengthens our conviction and will accelerate our marketing. »»
David Schilansky and Magali Richard, co -founders of Home Biosciences and One BioSciencecessaid: “When we co-founded Home Biosciences, we were responsible for building leading companies on their market. We believe that one biosciences has already exceeded this objective and that it will be a decisive turning point in precision oncology on a paradigm change scale. This new step is a validation of this exciting journey. »»
[1] The “ommal” sciences make it possible to capture large -scale information on the biological processes taking place at different levels of the cell – DNA (genomic), the expression of the genes (transcriptomic), to the production of proteins (proteomics), to the cellular metabolism (metabolomic).
[2] Led by Redmile Group and Blast, with the participation of Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Partners
